COMMUNIQUÉS West-GlobeNewswire

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
18/06/2025
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial [...]
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
18/06/2025
DIAG723 is supported by a groundbreaking preclinical profile demonstrating its disease-modifying potential WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics , a biotechnology company focused on [...]
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
18/06/2025
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita [...]
Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China
18/06/2025
BOSTON and SHANGHAI, June 18, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory [...]
Gradient Denervation Technologies annonce son admission au programme consultatif de la FDA sur le cycle de vie complet des produits pour le développement de son système de dénervation de l’artère pulmonaire
18/06/2025
PARIS, 18 juin 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies annonce ce jour son admission au programme pilote TAP (Total Product Life Cycle Advisory Program, programme consultatif sur le cycle de vie [...]
Gradient Denervation Technologies Announces Acceptance into FDA’s Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
18/06/2025
PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Gradient Denervation Technologies announced today that it has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot from the U.S. Food and Drug [...]
F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim
18/06/2025
Data reinforce olorofim’s potential as a first-in-class treatment for patients with invasive fungal diseases and limited or no antifungal treatment options MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- [...]
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
18/06/2025
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc . ( [...]
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
18/06/2025
Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18/06/2025
EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and [...]
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
18/06/2025
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the potential of [...]
Moleculin Participates in Virtual Investor “What This Means” Segment
18/06/2025
Watch the “What This Means" segment here HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of [...]
Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction
18/06/2025
Bolsters Prenetics’ pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term assets to approximately US$117 million Prenetics simplifies investment thesis as company focuses on high- [...]
Bionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy
18/06/2025
SAN DIEGO, June 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) recently participated in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025. The event [...]
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
18/06/2025
SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams
18/06/2025
WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR ) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it has expanded its [...]
Cannara réduit le coût de sa dette en abaissant son taux d’intérêt et en remboursant partiellement sa débenture convertible ; remporte le prix de la marque de l’année 2025
18/06/2025
MONTRÉAL, 18 juin 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara » , « la Société » , « nous ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de qualité [...]
Cannara Reduces Cost of Debt with Lower Interest Rate and Partial Debenture Repayment; Wins 2025 Brand of the Year
18/06/2025
MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
18/06/2025
Provides Accelerated Path to Market for PharmaTher’s Ketamine-based Proprietary Delivery Systems & Orphan Drug Designations, and Leveraging its Ketamine Product, having an FDA Approval Goal Date on August 9, 2025 [...]

Pages